Core Insights - Oncotelic Therapeutics, Inc. presented its research at SITC 2024, focusing on the TGFB2 therapeutics pipeline [1] - Dr. Cynthia Lee, VP of R&D, has been instrumental in leading R&D programs and the establishment of a GMP facility in San Diego [1] Research Presentations - Abstract Number 198 discusses the interaction of TGFB2 mRNA levels with Interferon-alpha receptor activation and its impact on overall survival in pancreatic ductal adenocarcinoma (PDAC) [1] - Abstract Number 218 evaluates the prognostic impact of TGFB2 mRNA levels in low-grade gliomas, in conjunction with Interferon-gamma receptor activation [1] - Abstract Number 1444 presents a meta-analysis comparing serious adverse events and survival outcomes in PDAC patients treated with mFOLFIRINOX or FOLFIRINOX [1] Company Overview - Oncotelic has a rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture, GMP Biotechnology Limited, and is involved in treatments for melanoma and Acute Myeloid Leukemia [2] - The company acquired PointR Data Inc. in November 2019 to enhance its AI-driven biotechnology capabilities [2] - Oncotelic is developing AL-101 for various conditions, including Parkinson's Disease and sexual disorders, addressing a significant patient population [2] - The first-in-class TGFB2 therapeutic for pancreatic cancer and glioblastoma is being developed through its joint venture, Sapu Bio [2]

SAN JOSE, Calif., Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, will be made publicly available on the Company's website at 12:15pm CT on November 8, 2024. Concurrently, the Company will issue a pre ...

MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pion ...

Core Insights - Candel Therapeutics announced preclinical results demonstrating the potent antitumor activity of CAN-3110 in melanoma models, suggesting potential for indication expansion beyond high-grade glioma [1][4] - CAN-3110 is a first-in-class oncolytic viral immunotherapy designed to target Nestin-expressing cancer cells, showing dual activity for oncolysis and immune activation [2][6] - The data presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting indicates significant tumor-specific cytotoxicity and systemic immune activation in melanoma models [4][5] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [7] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs [7] - CAN-3110 is currently in a phase 1b clinical trial for recurrent high-grade glioma, with previous results indicating improved median overall survival compared to historical controls [6][7] Research Findings - The poster presentation titled "Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma" highlights the mechanism of action and antitumor activity of CAN-3110 in preclinical melanoma models [3] - Preclinical data showed dose-dependent inhibition of tumor growth and tumor regression in melanoma-bearing mice treated with CAN-3110 [4] - The treatment was well-tolerated in animal models, with no dose-limiting toxicity reported [6]

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 studies BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced two upcoming presentations in November. The first presen ...

For the quarter ended September 2024, SITE CENTERS CORP. (SITC) reported revenue of $89.43 million, down 37.5% over the same period last year. EPS came in at $0.81, compared to $0.88 in the year-ago quarter.The reported revenue represents a surprise of -12.17% over the Zacks Consensus Estimate of $101.82 million. With the consensus EPS estimate being $0.87, the EPS surprise was -6.90%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to FFO of $1.32 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an FFO surprise of -6.90%. A quarter ago, it was expected that this company would post FFO of $0.96 per share when it actually produced FFO of $1.08, delivering a surprise of 12.50%. Over the last four quarters, the comp ...

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meetin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11690 SITE Centers Corp. (Exact name of registrant as specified in its charter) Ohio 34-1723097 (State or other jurisdiction of incorpora ...